Ultimate Exonic Coverage · Simple Workflow and Analysis · Exceptional Performance


Experience the MostComprehensive
Whole Exome Panel

Celemics WES is a comprehensive whole exome panel that covers the target regions of major WES panels in the market. With the target size of 37.1 Mb, the panel does not compromise performance in terms of NGS coverage and uniformity, enabling highly efficient and cost-effective sequencing of the whole human exome.

WES panel also perform well against hard-to-capture regions such as GC-rich regions. Regarding spike-in options, we also have the ability to customize our WES panel according to your needs by including mitochondrial or intronic regions at your request. The panel is also supported by Celemics Analysis Service (CAS), an end-to-end bioinformatics solution.

Celemics WES Panel
Features & Benefits

Complete Whole Exome Coverage

WES panel includes all exonic regions of major exome panels (37.1 Mb) with >98% coverage in addition to our proprietary probes that allows flawless capture performance even at ‘hard-to-capture’ regions, like GC-rich region. Experience the market-leading performance of on-target ratio and uniformity of Celemics’ WES panel.

Exclusive Technology
for Market-leading Performance

With Celemics’ proprietary probe and assay design technology, we are competent to provide a robust WES panel with market-leading on-target ratio and uniformity. 

For all panels that we design and manufacture, we always validate the panel and sequencing performance by fine-tuning the probe sets and reagents to ensure exceptional capture performance even in ‘hard-to-capture’ region to maximize the efficiency and provide the highest quality possible sequencing data for all our customers. 

Superior Performance in the Market

Celemics WES Panel shows exceptional performance compared to other competitor products in both germline and FFPE analysis.
(A) 1-PCT OFF BAIT (higher the better)
(B) Fold 80 base penalty (lower the better)

* Third-party laboratories (Certified Service Providers)
conducted a comparison study between the Celemics WES Panel, Company A and Company I panels. Reference materials NA12878, NA12891, NA12892 for germline analysis, and HD832 for FFPE analysis were used with same amount. Illumina instruments were used for the sequencing. The data from the three panels were downsampled to 5.4 Gb.

On target performance graph
Uniformity graph

Rapid One-Day Protocol

In order to reduce the hands-on and turn-around time for NGS, we have developed Celemics’ original One-Day protocol that does not require any heavy instruments.

Simplify your workflow with alternative methods for sample shearing, concentrating, and even QC and expedite your exome sequencing without compromising data quality.

Newly Developed Same-Day Workflow

Newly developed same day workflow

Complete Bioinformatics Support and Customization Service

Team of in-house Bioinformaticians have developed an exclusive analysis pipeline to simplify the data analysis process. Customer will simply ‘click’ to upload FASTQ to generate the ‘report’ for finalized analysis.

Different analytic-tiers for clinical interpretations or any other customizable types of analysis can also be supported to meet your analytic requirements.

CAS (Celemics Analysis Service) Workflow

CAS infograph
CAS report

Other Features

Other features image

Complete Walkaway 

Automate from sample preparation to hybridization on Hamilton, Bravo, or Sciclone.

Other features image

Flexible Customization
and Modification

Easy gene add-on service to expand your research discovery. ‘Make your own’ custom exome panel by adding spike-in mtDNA or intronic regions of interest.

Other features image

Flexible Integration with
various NGS Sequencers

Celemics’ blocker and assay optimization technology allows seamless integration with various sequencing platforms (Illumina, MGI, and Thermo Fisher)


Target size 37.1 Mb
Covered region CCDS, RefSeq, Genecode
Multiplexing option 4 / 8 / 12-plex enrichment
Platform Illumina, MGI and Thermo Fisher
(0.2X mean depth coverage uniformity)
> 96% > 95%
> 96% > 95%
Bioinformatics Support
  • 1. Primary Analysis: FASTQ to annotated VCF
  • 2. Secondary Analysis: CNV, Large InDel, TMB&MSI
  • 3. Tertiary Analysis: Clinical interpretation
  • Visualization curation: Heatmap, CNV visualization, statistical analysis, etc.
*PCT OFF BAIT : The fraction of passing filter bases aligned that are mapped away from any baited region

Related Products


Technical Resources

[Product Sheet] Whole Exome Sequencing Panel

[Product Overview] Celemics Target Enrichment Panel Overview

[Catalogue] Celemics Products & Service Catalogue_All Products & Service

Safety Data Sheets

MSDS_Whole Exome Sequencing Panel_Illumina

MSDS_Whole Exome Sequencing Panel_MGI

MSDS_Whole Exome Sequencing Panel_Thermo Fisher



Development of the phenylpyrazolo [3, 4-d] pyrimidine-based, insulin-like growth factor receptor/Src/AXL-targeting small molecule kinase inhibitor

Lee HJ, Pham PC, Pei H, Lim B, Hyun SY, Baek B, et al. Development of the phenylpyrazolo[3,4-d]pyrimidine-based, insulin-like growth factor receptor/Src/AXL-targeting small molecule kinase inhibitor. Theranostics. 2021;11(4):1918–36.



View Detail >

First-line pembrolizumab, trastuzumab, and chemotherapy in advanced HER2-2 positive gastric cancer with sequential genomic profiling

Chung HC, Bang YJ, S Fuchs C, Qin SK, Satoh T, Shitara K, et al. First-line pembrolizumab/placebo plus trastuzumab and chemotherapy in HER2-positive advanced gastric cancer: KEYNOTE-811. Future Oncol. 17(5):491–501.



View Detail >

British Journal of Cancer

p53 expression status is associated with cancer-specific survival in stage III and high-risk stage II colorectal cancer patients treated with oxaliplatin-based adjuvant chemotherapy

Oh HJ, Bae JM, Wen X, Jung S, Kim Y, Kim KJ, et al. p53 expression status is associated with cancer-specific survival in stage III and high-risk stage II colorectal cancer patients treated with oxaliplatin-based adjuvant chemotherapy. Br J Cancer. 2019 Apr;120(8):797–805.



View Detail >